Allergan and Editas announce $90M CRISPR deal
There really is enough CRISPR to go around. On Tuesday Allergan and Editas struck a deal to apply the gene-editing approaching in certain ocular conditions, including Leber congenital amaurosis.
There really is enough CRISPR to go around. On Tuesday Allergan and Editas struck a deal to apply the gene-editing approaching in certain ocular conditions, including Leber congenital amaurosis.
A ruling on the high-profile CRISPR patent interference case was delivered Wednesday, sending Editas shares up and causing others to dive. For all involved, the show will go on as other CRISPR licensing agreements still stand.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Flagship Ventures is now Flagship Pioneering, a rebrand that its CEO says better reflects its mission to discover and build first-of-its-kind science. It's a journey into the unknown — a journey that many U.S. innovators have taken before.
On Tuesday, judges heard verbal arguments from both sides of the CRISPR intellectual property fight, a technology that could prove to be the greatest biotech advance in recent history. But the outcome matters less than what is happening in the field right now.
Also, a new collar device has been designed to help protect athletes from head injuries, and it appears that the Zika virus can be sexually transmitted.